Celcuity Inc. (CELC) Stock Price & Analysis

Celcuity Inc. (CELC) closed at USD 69.46 on Wednesday, October 28, 2026, up 2.04% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 68.07; the Oct 28, 2026 session ranged USD 67.39–69.95 on volume of 1,125,891 shares. Market capitalization is $3.40B, with a 52-week range of USD 53.54–151.02 (NCM). Source: Nexqual, retrieved October 29, 2026 at 10:15 UTC.

Also available as compact Markdown for AI agents: nexqual.com/CELC.md

Key facts (CELC)

• Insider open-market sales, last ~7 months: 3 Form 4 filings, $323M; 1 not under a Rule 10b5-1 plan ($318M); 1 by opportunistic insiders (0 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.77 on a 1–5 scale) (13 analysts), mean target USD 154.72 (range 130–177).
• Total return with dividends: 1Y -6.1% vs S&P 500 +13.6%; 5Y +283.8% vs S&P 500 +79.8%.
• Next earnings: 2026-11-11, EPS estimate USD -1.51, revenue estimate $1.2M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CELC)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (CELC)

FCF yield -5.65% · Earnings yield -6.66% · Net cash $754M · EV $2.64B

Insider sales (SEC Form 4, open-market, last ~7 months) (CELC)

2 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (CELC)

Consensus Buy (mean 1.77 on a 1–5 scale), 13 analysts; mean target USD 154.72 (low 130, high 177).

Rating changes, last 120 days:

Total return (dividends reinvested) (CELC)

CELC earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

CELC recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

CELC suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 26, 2026.

CELC company outlook (results filed Aug 13, 2026)

• “Shipments of REVTORPYK are expected to begin late in the third quarter of 2026.”
• “Celcuity expects to provide further updates to results from both the PIK3CA MT and WT cohorts of VIKTORIA-1 at medical conferences in the fourth quarter. 1 st Line Setting Celcuity continues to advance gedatolisib combined with palbociclib and endocrine therapy in the first-line setting for patients with HR+/HER2- ABC through its ongoing Phase 3 VIKTORIA-2 clinical trial.”
• “Once the Phase 1/1b portion of the study is completed, Celcuity expects to select the recommended phase 2 dose level(s) and control arm options for the randomized Phase 2 portion of the study.”
• “The company expects to provide updated clinical data and additional visibility into its mCRPC development strategy during the fourth quarter of 2026.”

Quoted word-for-word from the SEC 8-K results press release.

CELC analyst estimates and revisions

CELC options: expected move

Options price a move of about ±17.4% (±$12.10) by Nov 20, 2026, which includes earnings on Nov 11, 2026. Over the last 8 reports the stock moved ±7.3% on average.

30-day implied volatility 81.2% vs 59.4% realized over the last 30 trading days. Put/call ratio (volume) 0.17. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 10:15 UTC)

Technical Analysis (CELC)

Nexqual's technical model rates CELC "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 10:15 UTC.

Analyst Ratings (CELC)

Wall Street analysts rate CELC "Buy" based on 13 analysts, with a mean price target of USD 154.72 (range USD 130–177), per Nexqual as of October 29, 2026 at 10:15 UTC.

Earnings (CELC)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 10:15 UTC.

Financials & Fundamentals (CELC)

Source: Nexqual, October 29, 2026 at 10:15 UTC.

Financial Health Score (CELC)

Nexqual rates Celcuity Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 10:15 UTC.

Ownership (CELC)

Source: Nexqual, October 29, 2026 at 10:15 UTC.

Leadership (CELC)

Celcuity Inc. is led by Brian F. Sullivan, Co-Founder, Chairman & CEO, per Nexqual as of October 29, 2026 at 10:15 UTC.

Major Backers & Investors (CELC)

Notable institutional backers of Celcuity Inc. include Baker Bros. Advisors, LP, Avoro Capital Advisors LLC, RTW Investments LP, according to Nexqual as of October 29, 2026 at 10:15 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 10:15 UTC.

From Celcuity Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)

Key Strengths & Strategy (as disclosed to the SEC)

• We are also required to make milestone payments to Pfizer upon achievement of certain development and commercial milestone events, including a $5.0 million milestone payment we made in January 2026 following FDA acceptance of our NDA submission, up to an aggregate of $335.0 million.
• Many of the companies against which we may compete have significantly greater financial resources and expertise than we do in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products. are several PI3K, AKT, and mTOR inhibitors approved by the FDA, including PIQRAY and AFINITOR from Novartis AG, TRUQAP from AstraZeneca plc, ITOVEBI from F.
• If gedatolisib ultimately receives FDA approval for the treatment using internal duration of treatment estimates and pricing assumptions consistent with currently available novel therapeutics for breast cancer, we estimate the total addressable market for gedatolisib in the second-line setting is more than $5.0 billion.
• NDA approval of a new chemical entity ("NCE"), which is a drug (i.e., gedatolisib) that contains no active moiety that has been approved by the FDA in any other NDA, that drug receives five years of marketing exclusivity during which the FDA cannot accept any Abbreviated New Drug Application ("ANDA"), seeking approval of a generic version of that drug.

Partnerships

• We also rely on trade secrets, trademarks, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position. entered into the Gedatolisib License Agreement with Pfizer in April 2021, pursuant to which we acquired exclusive worldwide rights under Pfizer patents and know-how to develop, manufacture and commercialize gedatolisib.
• Given the significant penetration our research is suggesting we can achieve, we believe it is reasonable to estimate that a second-line indication for gedatolisib could potentially generate peak revenue of up to $2.5 billion annually. success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, to operate without infringing the proprietary rights of others, and to prevent others from infringing our proprietary rights.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 10:15 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt